Engineering and combining oncolytic measles virus for cancer therapy
Abbreviations
Keywords
Cited by (0)
Mathias F. Leber, MD, PhD, is a clinician-scientist, and currently works as a Senior Research Associate and Head of Laboratory at the Ottawa Hospital Research Institute (Cancer Therapeutics Program). His main research interests are novel immuno-virotherapy approaches and the genetic engineering of oncolytic viruses using small RNAs.
Serge Neault is a Ph.D. student at the University of Ottawa in Ottawa, Canada. His current research interest is in the design of oncolytic viruses for a novel treatment of cancers.
Elise Jirovec recently completed her Bachelor’s degree in Biopharmaceutical Science at the University of Ottawa and is starting her Master’s degree in Innovative Medicine at Heidelberg University. Her current research interest is in the design of a novel virotherapy for cancer treatment.
Russell Barkley is a Master’s student at the University of Ottawa with a deep curiosity for all things unknown. He enjoys creating fresh ideas and being puzzled by new discoveries. Outside of the laboratory he can be found at the local ice hockey rink.
Aida Said obtained her MSc. in Neuroscience from the Faculty of Medicine, University of Ottawa. She is currently pursuing a PhD degree in Microbiology and Immunology at the Faculty of Medicine, University of Ottawa. Her research interest is focused on developing treatments for cancer by combining oncolytic measles virus with kinase inhibitors.
John C. Bell, PhD, is a Senior Scientist in the Cancer Therapeutics Program at the Ottawa Hospital Research Institute and a Professor of Medicine at the University of Ottawa. He is also the Scientific Director of BioCanRx, a network of scientists, clinicians, cancer stakeholders, academic institutions, NGOs and industry partners aiming at the development of leading-edge immune oncology therapies. John is also a co-founder of Turnstone Biologics, a company developing viral immunotherapeutics against cancer. Since 2012, he heads the Terry Fox-funded Canadian Oncolytic Virus Consortium, which is developing virus-based cancer therapeutics, and he is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. In addition, John is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a fellow of the Royal Society of Canada.
Guy Ungerechts, MD, PhD, is the Deputy Director of the Department of Medical Oncology at the Heidelberg University Hospital in Heidelberg, Germany, and Head of the Clinical Cooperation Unit “Virotherapy” at the German Cancer Research Center in Heidelberg, Germany. He is also the co-founder of CanVirex, a spin-off company from the University Hospital Heidelberg, focused on the development of novel immunovirotherapies. Guy is an affiliated investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program). His main research interest is the translation of oncolytic immunotherapies from bench to bedside.